12.11.2014 11:00:00 CET
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SOUTH AFRICA OR ANY OTHER JURSIDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.
Nexstim Plc appoints Pareto Securities as liquidity provider
Helsinki, 12 November 2014 at 12.00 am
Following the publication of the final results of Nexstim Plc's ("Nexstim" or the "Company") initial public offering (the "Offering") on 10 November 2014, and in accordance with the First North rules, Nexstim has on 11 November 2014 appointed Pareto Securities AB as liquidity provider on Nasdaq First North Finland and Nasdaq First North Sweden.
The bid quote and the ask quote under the liquidity provision agreement shall be at least EUR 4,000 on Nasdaq First North Finland and SEK 20,000 on Nasdaq First North Sweden. The maximum spread on both marketplaces shall be 4%.
The services under the liquidity provision agreement will begin on 14 November 2014, which is also the expected first day of trading in the Company's shares both on Nasdaq First North Finland (with the ticker NXTMH) and on Nasdaq First North Sweden (with the ticker NXTMS). The liquidity provision agreement between Nexstim and Pareto Securities AB will stay in force for six months.
The Company's Certified Adviser under the First North rules is UB Capital Ltd.
Additional information on the Offering is available in the prospectus published by Nexstim on 13 October 2014, as supplemented on 30 October 2014, available at www.nexstim.com/IPO.
For further information please visit www.nexstim.com or contact:
Nexstim Janne Huhtala, Chief Executive Officer | +358 40 8615046 janne.huhtala@nexstim.com |
UB Capital Ltd | +358 (9) 2538 0225 |
Consilium Strategic Communications Mary-Jane Elliott Amber Bielecka Ivar Milligan Laura Thornton | +44 (0)20 3709 5700 nexstim@consilium-comms.com |
About Nexstim
Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform the company has developed a device for stroke therapy, called Navigated Brain Therapy (NBTŪ). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBTŪ and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. For more information please visit www.nexstim.com.
IMPORTANT NOTICE
This announcement is not a prospectus. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. The Offering is made solely on the basis of the prospectus approved by the Finnish Financial Supervisory Authority on 10 October 2014, as supplemented on 30 October 2014, and passported by way of notification to the Swedish Financial Supervisory Authority.
This communication is not addressed to the public in any Member State of the European Economic Area other than Finland and Sweden. With respect to each Member State of the European Economic Area other than Finland and Sweden (each, a "Relevant Member State"), no action has been undertaken to date to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State. As a result, this communication is only addressed to and directed at qualified investor in the Relevant Member States in circumstances not requiring the Company to publish a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State).
This announcement is not an offer for sale nor a solicitation of an offer to buy any securities in the United States or outside the European Economic Area. The securities referred to in this announcement may not be offered or sold in or into the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Nexstim has not registered and will not register any part of its contemplated offering in the United States nor will it offer any securities to the public in the United States.
This communication is only being distributed to and is directed only at (i) persons who are outside the United Kingdom, or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order, and (iv) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
Securities in the Company have not been, and will not be, registered under the applicable securities laws of Australia, Canada, Hong Kong, Japan or South Africa and may not be offered or sold within Australia, Canada, Japan or South Africa or to, or for the account or benefit of, citizens or residents of Australia, Canada, Hong Kong, Japan or South Africa except under circumstances which will result in full compliance with the applicable laws and regulations promulgated by the relevant regulatory authorities in effect at the relevant time.
This announcement contains forward looking statements. These forward looking statements include statements that are not historical facts and statements concerning inter alia Nexstim's future revenues, financial position, financial standing, prospects, growth, strategies and its plans, beliefs and current expectations in relation to its field of business. By their very nature, forward looking statements involve inherent risks and uncertainties, since they relate to events or result from circumstances that may or may not occur in the future, and therefore they only describe the circumstances prevailing when the statement is given. Nexstim cautions that forward looking statements or historical facts do not guarantee future performance and that its true revenues, financial position and financial standing and the development of the industry may significantly differ from the forward looking statements presented in this release. The Company does not intend and does not assume any obligation to update any forward looking statement contained herein.